National Institute of Allergy and Infectious Diseases (NIAID)
Strategic Plan for Covid-19 Research-2021 Update
Priority 1: Advance basic research on SARS-CoV-2 biology, pathogenesis and transmission
Priority 2: Identify and test promising COVID-19 therapeutics
Priority 3: Develop and test next-generation COVID-19 and pan-coronavirus vaccine candidates
Priority 4: Characterize, prevent and treat post- acute sequelae of SARS-CoV-2 infection (PASC)
Effective communication between the NIAID and general public of resources to understand the COVID-19 related strategic plan is needed to successfully reduce COVID-19 spread. Giving the public access to information that can be easily read will have a big impact on how we understand the molecular world that drives our daily actions. Awareness of COVID-19 pandemic prevention measures will "prioritize the inclusion of high-risk and minority populations to ensure broad testing and validation in the most vulnerable populations." Research development to effectively communicate the ideology of disease spread prevention is necessary to invoke policy that will save lives. The meaningful ways we develop statistical analysis of human interactions will produce positive results to prevent further spread. Positive collaborations with U.S. government agencies and other key U.S. global partners will collect data to be used in clinical practices and public health initiatives. Public health safety precautions like testing new drugs for therapeutics will improve development of direct acting antivirals against SARS-CoV-2. Positive responses of clinical trials for special populations, high-risk and minority populations and pregnant or breastfeeding women to engage in clinical analysis.
Stopping the Spread of COVID-19 is an important task for the current administration.
Check out the NIAID website page!